HC Wainwright Issues Positive Estimate for JSPR Earnings

Jasper Therapeutics, Inc. (NASDAQ:JSPR) – Analysts at HC Wainwright increased their Q3 2026 EPS estimates for shares of Jasper Therapeutics in a research note issued on Monday, August 17th. HC Wainwright analyst E. Bodnar now expects that the company will earn $0.16 per share for the quarter, up from their prior estimate of ($0.47). HC Wainwright currently has a “Buy” rating on the stock. The consensus estimate for Jasper Therapeutics’ current full-year earnings is ($1.47) per share. HC Wainwright also issued estimates for Jasper Therapeutics’ Q4 2026 earnings at ($0.42) EPS, FY2026 earnings at ($0.89) EPS, FY2027 earnings at ($1.31) EPS, FY2028 earnings at ($1.62) EPS, FY2029 earnings at ($2.23) EPS and FY2030 earnings at ($2.76) EPS.

Several other research firms also recently commented on JSPR. Piper Sandler began coverage on Jasper Therapeutics in a research report on Wednesday, August 12th. They set an “overweight” rating and a $2.00 target price for the company. TD Cowen cut Jasper Therapeutics from a “buy” rating to a “hold” rating in a research report on Friday, May 15th. Wall Street Zen lowered Jasper Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday. Weiss Ratings reiterated a “sell (e+)” rating on shares of Jasper Therapeutics in a research note on Friday, July 17th. Finally, Royal Bank Of Canada set a $3.00 price objective on Jasper Therapeutics and gave the company a “sector perform” rating in a report on Friday, May 15th. Six equities research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, Jasper Therapeutics has a consensus rating of “Moderate Buy” and an average price target of $8.17.

Jasper Therapeutics Trading Down 10.9%

JSPR stock opened at $0.75 on Wednesday. Jasper Therapeutics has a 1-year low of $0.32 and a 1-year high of $3.05. The firm has a market cap of $21.00 million, a P/E ratio of -0.47 and a beta of 3.02. The business’s 50 day moving average is $0.61 and its 200-day moving average is $0.89.

Jasper Therapeutics (NASDAQ:JSPR) last posted its quarterly earnings results on Friday, August 14th. The company reported ($0.10) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.27) by $0.17.

Hedge Funds Weigh In On Jasper Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the business. Goldman Sachs Group Inc. increased its stake in shares of Jasper Therapeutics by 11.2% in the first quarter. Goldman Sachs Group Inc. now owns 233,758 shares of the company’s stock valued at $1,005,000 after buying an additional 23,453 shares in the last quarter. Acadian Asset Management LLC acquired a new position in Jasper Therapeutics during the 1st quarter worth about $46,000. JPMorgan Chase & Co. grew its holdings in Jasper Therapeutics by 1,074.7% during the 2nd quarter. JPMorgan Chase & Co. now owns 65,088 shares of the company’s stock worth $361,000 after acquiring an additional 59,547 shares during the last quarter. XTX Topco Ltd bought a new stake in Jasper Therapeutics during the 2nd quarter worth about $152,000. Finally, Marshall Wace LLP acquired a new stake in Jasper Therapeutics in the 2nd quarter valued at about $281,000. Institutional investors and hedge funds own 79.85% of the company’s stock.

Jasper Therapeutics Company Profile

Jasper Therapeutics, Inc (NASDAQ: JSPR) is a clinical-stage biopharmaceutical company focused on translating advances in immunobiology into therapies for serious and rare diseases with unmet medical needs. The company’s research and development efforts center on engineered biologics and cell-based approaches designed to address complications in hematologic conditions and improve outcomes in transplant medicine.

Central to Jasper’s pipeline is JSP191, a monoclonal antibody targeting the CD117 receptor, which is being evaluated to enhance donor hematopoietic stem cell engraftment in patients undergoing stem cell transplantation.